Skip to content

Andy & Sofia

Menu
  • The book
  • What is NEMO?
    • Clinical Presentation of NEMO
    • Diagnosis of NEMO
    • Therapy for NEMO
    • Expectations for the Patient
  • From Andy’s Perspective
    • Finding Nemo
    • Some of my heroes
    • Good things in the bad
  • Resources
  • Photos
  • Talks
  • Contact Us
  • Blog
Menu

Gene Therapy Is Facing a Crucial Hearing @ The New York Times

Posted on March 3, 2005 by Andres Trevino

More about gene therapy..
Interesting data:
nytimes.gif

By GARDINER HARRIS; Published: March 3, 2005
The French study was once hailed as one of the first breakthroughs in gene therapy: 10 children suffering from a rare immune disorder were largely cured. But three of those children have since developed leukemia, and one of the three has died.
For years, gene therapy was heralded as a technology that would soon yield blockbuster drug innovations. The National Institutes of Health issued thousands of grants to pursue the research, hundreds of patents have been granted on the technology, and more than 150 biotechnology companies have been created in the last 15 years to exploit it. In 1997 alone, the peak year, 24 such companies were created, said Dr. Sheldon Krimsky, a professor at Tufts University.
Gene therapy’s disappointing history is mirrored in other medical technologies once highly promoted, like high-throughput chemical screening and the decoding of the human genome. Reaping the fruits of such technological advances is taking much longer than executives in biotechnology and pharmaceuticals once suggested. As a result, the industries are suffering a drought of new products and are trying to explain why their laboratories have burned through so much money in recent years with so little to show for it.
Many of the companies established since 1990 to pursue gene therapy work have since shifted to other technologies. Cell Genesys, in South San Francisco, Calif., once focused entirely on gene therapy, but in 2001 it spun off much such research into privately held Ceregene, based in San Diego.
“We’re just a cancer company now,” said Ina Cu, a Cell Genesys spokeswoman.
Despite the problems, gene therapy is still routinely heralded as the next big thing, and the field’s researchers get a bit defensive when discussing the many problems that have plagued it. But several top researchers agreed in interviews that much of the early optimism had been wrongheaded and that marketable cures were years away.

Read all the article @ NY Times here.
Dr. Raif Geha, (website) Chief of Immunology at Children’s Hospital Boston told me about 2 weeks ago that ten more years are needed to make gene therapy available and once he does that he will move to the caribbean..

Category: + English, NEMO Gene, News & Blogs, Primary Immunodeficiency

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

  • Analysis of Comments to Sofia’s DoS interview
  • “Resilience is not about being tough; its about being alive. If you are alive, you will face challenges. How you respond to them is what matters.”
  • The highest form of wisdom is kindness
  • “When you are good to others, you are best to yourself” -Benjamin Franklin
  • “Success is not final; failure is not fatal: it is the courage to continue that counts.” -Winston Churchill.
  • + English
  • + Español
  • Andy's Update
  • Autographs
  • Book
  • Bugs
  • Ectodermal Dysplasia
  • Family & Friends
  • Fundraising & Gifts
  • Gadgets
  • Glossary
  • Hospitals
  • Invitro Fertilization
  • Marathon
  • Medications
  • NEMO Gene
  • News & Blogs
  • Other
  • PGD
  • Phrases
  • Pictures
  • Primary Immunodeficiency
  • Savior Siblings – PGD
  • School
  • Sofia's Update
  • Sports
  • Stem Cell Transplant
  • Stem Cells
  • Uncategorized

Contact us

andy@andy.org.mx
© 2025 Andy & Sofia | Powered by Minimalist Blog WordPress Theme